LAVA Therapeutics NV
NASDAQ:LVTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.9889
4.03
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
LAVA Therapeutics NV
LAVA Therapeutics NV
Selling, General & Administrative
LAVA Therapeutics NV
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Selling, General & Administrative
-$12.7m
|
CAGR 3-Years
-67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Selling, General & Administrative
-$199.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-55%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Selling, General & Administrative
-€14.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Selling, General & Administrative
-$58.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-13%
|
|
|
argenx SE
XBRU:ARGX
|
Selling, General & Administrative
-$1.1B
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-78%
|
CAGR 10-Years
-94%
|
|
|
Merus NV
NASDAQ:MRUS
|
Selling, General & Administrative
-$75.3m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
See Also
What is LAVA Therapeutics NV's Selling, General & Administrative?
Selling, General & Administrative
-12.7m
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Selling, General & Administrative amounts to -12.7m USD.
What is LAVA Therapeutics NV's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 3Y
-67%
Over the last year, the Selling, General & Administrative growth was 10%. The average annual Selling, General & Administrative growth rates for LAVA Therapeutics NV have been -67% over the past three years .
You don't have any saved screeners yet
